ISAB: Sharp revenue drop and ongoing losses; financing and going concern remain key risks

About this update from Inhalation Sciences Sweden Ab

Revenue declined sharply in 2025, with a significant operating loss and ongoing negative cash flow. The order backlog improved, but future financing remains uncertain, and a strategic review for potential sale is underway. Material uncertainty exists regarding going concern.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Inhalation Sciences Sweden Ab